Human adenovirus type 5 (recombinant) is under clinical development by Shanghai Sunway Biotech and currently in Phase I for Malignant Ascites. According to GlobalData, Phase I drugs for Malignant Ascites does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Human adenovirus type 5 (recombinant) LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Human adenovirus type 5 (recombinant) overview
Shanghai Sunway Biotech overview
Shanghai Sunway Biotech (Sunway Biotech) is a drug development company that develops oncolytic viruses for cancer therapy. The company’s pipeline products include H101 recombinant human adenovirus type 5 injection and h103 oncolytic recombinant adenovirus injection. It also provides Oncorine, an oncolytic adenoviruses medication. Sunway Biotech conducts clinical studies of lung cancer, pancreatic cancer, liver cancer and malignant effusion. The company offers cGMP cell and virus bank manufacturing, process development and pilot studies, quality assurance and control, and lot manufacturing services. It also develops technologies such as cell culture technologies, downstream processing technologies and fermentation technologies. Sunway Biotech is headquartered in Shanghai, China.
For a complete picture of Human adenovirus type 5 (recombinant)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
